Report projects heart failure market to increase by 13.7% per year until 2025

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

A new report from GlobalData estimates the market for heart failure treatments is expected to grow from $3.2 billion in 2015 to $11.8 billion in 2025, representing a 13.7 percent compound annual growth rate.

The company’s projection includes the U.S., United Kingdom, France, Germany, Italy, Spain and Japan.

GlobalData, a research and consulting firm,  estimates that sales of sacubitril/valsartan (Entresto, Novartis) will account for much of the growth and reach peak sales of $5.1 billion in 2022. However, sales of the drug have been far below analysts’ expectations so far.

In the first quarter of 2016, Novartis  reported just $17 million in U.S. sales for the twice-daily oral medication, which the FDA  approved in July 2015.

“GlobalData has identified high pricing and the general reluctance of cardiologists and physicians to adopt new therapies as the main barriers to the uptake of this drug,” Elizabeth Hamson, PhD, GlobalData’s analyst covering cardiovascular and metabolic disorders, said in a news release. “Despite this, it is expected that Entresto will begin to dominate the global heart failure space, particularly after its label expansion to heart failure with preserved ejection fraction, which is expected to occur in 2020, making it the strongest driver of market growth.”

GlobalData’s report indicates that the chronic heart failure market will increase from $3.1 billion in 2015 to $10.3 billion in 2025, which represents a 12.9 percent compound annual growth rate.

During that same time period, the market for acute heart failure is expected to increase from $188.1 million to $1.5 billion for a compound annual growth rate of 23.0 percent.

GlobalData’s projections include the expected launches of ularitide (Cardiorentis) and serelaxin (Novartis) to treat acute heart failure. In May 2014, the FDA  rejected the approval of serelaxin. The FDA  granted ularitide a fast track designation in December 2015.

The report contains on medications from the following companies: Amgen, Bayer, Bristol Myers Squibb, Cardiorentis, Cytokinetics, Daiichi Sankyo, Heart Metabolics, Lee’s Pharmaceutical Holdings, Les Laboratoires Servier, Merck, Novartis, Ono Pharmaceuticals, Pfizer and Trevena.